Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics

Eli Lilly’s obesity pill Foundayo logged 3,707 U.S. prescriptions in its latest week, but shares fell nearly 5% as the launch trailed investor expectations and comparisons to Novo Nordisk’s Wegovy fueled a reset in sales forecasts. The FDA issued three national priority review vouchers for psychedelic medicine programs, while Regeneron reached a drug-pricing deal that includes a three-year tariff reprieve, Medicaid most-favored-nation pricing for certain drugs, and participation in TrumpRx. Amgen and BridgeBio Oncology both announced leadership changes, and Novo reported positive late-stage results for oral semaglutide in adolescents with type 2 diabetes.

Analysis

The near-term signal is less about one weak weekly print and more about the asymmetry in launch expectations. In obesity, prescription velocity compounds early, so a softer ramp can quickly force model cuts, retailer inventory caution, and sales-force reallocation risk across the category; the first 6-10 weeks matter disproportionately for 2026 consensus. The market is starting to treat GLP-1 pill adoption as a share-gain proxy against Novo, but the bigger second-order issue is whether oral obesity remains an incremental market or simply cannibalizes injectables with lower net revenue per patient.

Novo’s positive pediatric diabetes readout is strategically more important than the market is likely pricing. It extends semaglutide’s duration curve into a younger cohort, which matters for lifetime value, persistence, and payer engagement even if the near-term revenue pool is modest. More importantly, it supports the idea that oral semaglutide can become the “entry point” franchise for chronic metabolic disease, potentially cushioning Novo if obesity-pill pricing comes under pressure.

The FDA voucher action is an underappreciated policy inflection for psychedelics because it lowers regulatory friction more than it changes fundamental efficacy risk. For CMPS, the real value is not the voucher itself but the signaling effect: capital markets may now assign a higher probability to a faster path through review, which can reduce cost of capital for the entire cohort. Still, this remains a multi-quarter story, and any binary trial or safety setback would overwhelm the policy tailwind.

Regeneron’s pricing deal looks benign on headline economics, but the second-order read-through is that the sector is increasingly paying a small manufacturing/PR toll to de-risk tariff and pricing headlines. That should compress event risk premia across large-cap biotech, especially for names with U.S. manufacturing flexibility. Amgen’s management changes are more subtle: pulling AI/data under R&D suggests a push to improve pipeline productivity, but the stock likely needs evidence over the next 6-12 months before the market assigns any real multiple uplift.

Key Decisions for Investors

• Fade the NVO move tactically: buy NVO on pullbacks over the next 1-2 weeks, or sell downside puts, because the market is likely underweighting the lifetime-value benefit of the adolescent semaglutide data and the broader franchise durability.
• Short-term relative value: long NVO / short LLY for 2-6 weeks if prescription momentum remains the key debate; NVO has cleaner optionality from multi-form-factor semaglutide, while LLY is most exposed to a launch-multiple reset if weekly scripts fail to inflect.
• Buy CMPS call spreads or a small equity starter position for a 3-6 month horizon; the FDA voucher is a catalyst for multiple expansion, but size should be limited because the binary clinical/regulatory risk remains dominant.
• Reduce event-risk exposure in large-cap biotech by favoring REGN over peers with less manufacturing optionality; the tariff/pricing overhang is now a lower-probability tail risk, so names that can keep negotiating from strength should rerate modestly over the next quarter.
• Watch AMGN as a 6-12 month operational-story long only on pullbacks: the AI/data reorganization is a governance-positive if it translates into pipeline efficiency, but absent proof it is not enough for an aggressive immediate add.